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Abstract 
Endoscopic ultrasound (EUS) is an important tool 
in the staging of gastrointestinal cancers. This review 
highlights the use of EUS in the staging of 
gastrointestinal luminal malignancies and compares the 
performance of EUS with other imaging modalities (CT, 
MRI and PET-CT) in the staging of these malignancies. 
Management algorithms in the staging of these 
malignancies are also presented. 
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Introduction 
Endoscopic Ultrasound (EUS) allows accurate T 
staging of gastrointestinal luminal malignancies, which 
is essential to plan the optimal strategy to treat these 
tumors. EUS is usually carried out after other imaging 
modalities (CT scan, PET-CT or MRI) have excluded 
the presence of distant metastases or when an equivocal 
lymph node on PET-CT needs cyto-histological 
confirmation of invasion. Different EUS endoscopes are 
available. Radial echoendoscopes give the best 
identification of the different layers of the intestine and 
at frequencies of 7.5 and 12 MHz allow a penetration of 
8cm and 3cm respectively. Mini-probes are able to 
distinguish the different layers with greater accuracy in 
view of their higher frequencies (20 MHz). The depth of 
penetration is lower at higher frequencies but miniprobes 
provide greater resolutions that are ideal for evaluating 
early-stage cancers. The linear echoendoscope allows the 
acquisition of samples for cytology or histology and is 
needed when Fine Needle Aspirates (FNA) of lesions are 
planned.  
A Pubmed search using the terms oesophageal 
cancer, gastric cancer, rectal cancer and endoscopic 
ultrasound was carried out. Studies comparing accuracy, 
sensitivity and specificity for T and N staging of EUS 
with the accuracy, sensitivity and specificity of other 
imaging modalities (CT, MRI, PET) were analyzed. 
Mangement algorithms based on established guidelines 
will be presented.
1,2
 
 
Oesophageal Cancer 
Oesophageal cancer is associated with a poor 
prognosis. In a pan-European study which analysed 
5,499 patients with oesophageal cancer from 24 
countries there were 1- and 5-year survival rates of 
33.4% and 9.8% respectively.
3
 Staging in oesphageal 
cancer (Table 1)
4
 allows the identification of the optimal 
treatment strategy in this condition. 
Staging for esophageal malignancy requires 
Computed Tomography (CT – for the identification of 
distant metastases) and EUS (for T and N staging). 
Tumor stage is predictive of surgical resectability. The 
most important role for EUS is in the initial triage of 
patients to decide who should receive neoadjuvant 
chemo/radiotherapy and who would benefit from 
immediate surgical resection. Patients with any nodal 
involvement typically receive preoperative neoadjuvant 
therapy, while patients with T1 or T2 tumors (without 
nodal involvement) undergo immediate surgical  
resection. The high-frequency EUS mini-probe can 
accurately detect intramucosal cancer in 70-88% of 
patients and submucosal invasive cancer in 83-94% of 
patients.
5
  
Initial overall stage by EUS, the presence of LN 
metastases, and the presence of celiac adenopathy are all 
predictive factors of survival.
6
 Studies have shown better 
survival in patients with few or no suspicious regional 
LN on EUS.
7
 The median survival rates were 66 months 
for no regional LN, 14.5 months for 1-2 LN, and 6.5 
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months for >2 suspicious LN.
7
 Since the number of 
suspicious periesophageal LN detected by EUS is 
inversely associated with survival in patients with 
esophageal adenocarcinoma, N staging is very important 
before surgery. For this reason, the Surveillance, 
Epidemiology, and End Results database suggests that 
tumor length and number of LN should be routinely 
reported as part of the staging system.
8
 
The management algorithm for esophageal cancer is 
described in Figure 1.
9
  
 
Figure 1: Management of Oesophageal Cancer – from 
staging to treatment (PET- Positron emission 
tomography; CT Scan-Computed tomography scan; EUS 
+/- FNA-Endoscopic ultrasound with or without Fine 
Needle Aspiration; Neoadjuvant therapy – 
Chemo/Radiotherapy)
7
 
 
Once passage with the echoendoscope through the 
stricture is possible, staging of esophageal cancer is done 
by inspecting the liver, celiac axis and gastrohepatic 
ligament for the presence of liver or LN metastasis. The 
esophageal lesion and the mediastinum are then 
examined to identify depth of invasion and peritumoral 
and mediastinal adenopathy.
7 
EUS is also important in 
restaging after patients receive chemo/radiotherapy.  
However, EUS is not accurate after neoadjuvant 
chemo/radiotherapy since it is unable to differentiate 
tumor from necrosis or inflammatory reaction.
10
 Other 
studies however indicate that EUS and EUS-guided 
FNA can be helpful in identifying residual tumor in the 
LN after preoperative chemo/radiotherapy in patients 
who may benefit from surgery.
11 
EUS is superior to CT scan in tumor (T) staging of 
esophageal cancer. Thirteen studies of patients with 
esophageal cancer undergoing EUS showed 71-100% 
sensitivity and 67-100% specificity while 5 studies in 
patients undergoing CT scan showed 40-80% sensitivity 
and 14-97% specificity.
12
 N staging also appears to be 
superior with 60-97% sensitivity and 40-100% 
specificity for EUS versus 40-73% sensitivity and 25-
67% specificity for CT scan.
12
 In addition, FNA of 
suspicious LN allows cytological confirmation of 
malignancy. The sensitivity in staging LN increases 
from 71% with EUS to 83% with EUS-FNA.
13 
EUS also 
appears to be superior to PET in T staging and in 
detecting peritumoral and celiac LN.
14
 FDG-PET has a 
15% false-positive rate in the detection of distant and 
hematogenous metastases.
14
 EUS FNA can be used to 
confirm positive findings on PET scans.
15
 
 
The combination of CT, PET and EUS decreases 
the number of unnecessary operations by half when 
compared with CT alone.
14 
Detection of previously 
unidentified celiac axis metastases intraoperatively also 
decreased significantly when CT was combined with 
PET or EUS. EUS also detects occult liver metastases, 
though it visualizes only the medial two thirds of the 
liver. FNA can be performed for histological 
confirmation of liver metastasis.
16
 
 
 
Gastric Cancer 
Gastric cancer is the second leading cause of cancer 
related deaths worldwide.
17
 Accurate staging of gastric 
cancer (Table 1) by determining tumor extent and nodal 
involvement is important in the treatment algorithm 
(Figure 2).  
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Table 1: American Joint Committee on Cancer TNM 
Classification for Esophageal and Gastric Cancers
2
 
 
 
 
 
 
 
 
Figure 2: Management of Gastric Cancer – from 
staging to treatment (CT Scan-Computed tomography 
scan; EUS +/- FNA-Endoscopic ultrasound with or 
without Fine Needle Aspiration; EMR-Endoscopic 
Mucosal Resection; Neoadjuvant therapy - 
chemotherapy)
27
 
 
 Evidence shows that 5-year survival rate for early 
gastric cancer confined to the mucosa or submucosa is 
>75% following resection but < 30% with distant 
metastasis or with the involvement of >15 (N3) LN.
18
 
Surgery is the recommended treatment of choice for 
localized gastric cancer with endoscopic mucosal 
resection (EMR) reserved for cancers limited to the 
mucosa. Neoadjuvant chemotherapy is recommended for 
patients with deeper invasion. CT is important to 
exclude distant metastases but lacks accuracy in T and N 
staging of gastric cancer
19
, while EUS has much greater 
accuracy in evaluating the depth of invasion of primary 
gastric cancer.
19-21
 In addition, EUS-guided FNA of LN 
adds to the accuracy of nodal staging.
21
 
The overall sensitivity of EUS in determining T 
stages is best for T1 and T3 lesions, whereas EUS is 
least accurate for T2 and T4 lesions. In a meta-analysis 
of 54 studies carried out between 1988 and 2010, the 
pooled sensitivity was 83% for T1 lesions, 65% for T2, 
86% for T3, and 66% for T4 lesions.
22
 This is believed 
to occur because identifying T1 and T3 invasion is 
facilitated by the hypoechogenicity of the muscularis 
mucosa and muscularis propria while identifying T4 
invasion is made difficult by the limited depth of 
penetration of the ultrasound waves. The pooled 
sensitivity for N staging was 69% with a specificity of 
84%.
22
 In situations where malignant LN can be difficult 
to distinguish from benign nodes, EUS-FNA cytology 
and biopsy may offer better diagnostic yields. 
A systematic review comparing the diagnostic T 
stage accuracy of EUS with CT revealed an accuracy of 
65-92% with EUS and an accuracy varying between 
Oesophageal 
Cancer 
 
T Stage  
Tx Tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Invades lamina propria or 
submucosa 
T2 Invades muscularis propria 
T3 Invades adventitia 
T4 Invades adjacent structures 
N Stage  
Nx Regional nodes cannot be 
assessed 
N0 No regional LN metastasis 
N1 Regional LN metastasis 
M Stage  
Mx Distant metastasis cannot be 
assessed 
M0 No distant metastasis 
M1 Distant metastasis 
Gastric Cancer  
T Stage  
Tx Tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Invades lamina propria or 
submucosa 
T2 Invades muscularis propria or 
subserosa 
T3 Penetrates serosa without 
invasion of adjacent structures 
T4 Invades adjacent structures 
N Stage  
Nx Regional nodes cannot be 
assessed 
N0 No regional LN metastasis 
N1 Metastasis in 1-6 regional LN 
N2 Metastasis in 7-15 regional LN 
N3 Metastasis in >15 regional LN 
M Stage  
Mx Distant metastasis cannot be 
assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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77.1-88.9% with CT.
23
 Another review comparing N 
stage sensitivities and specificities of EUS with CT 
showed that EUS had 71% sensitivity and 49% 
specificity while CT had 80% sensitivity and 78% 
specificity.
24 
CT is also superior in detecting distant 
metastasis and both techniques are complementary for 
overall staging. EUS is required in the absence of distant 
metastases since management decisions will then depend 
on the depth of invasion.
 
Better surgical outcomes are obtained in patients 
with locally invasive gastric cancer who receive 
preoperative neoadjuvant chemotherapy. However, 
following chemotherapy, the accuracy of CT and EUS 
for both T and N staging drops significantly (57% and 
47% for T staging and 37% and 39% for N staging).
25
 
EUS is more sensitive than transabdominal ultrasound, 
CT and laparoscopy for the detection of intraperitoneal 
fluid, which is usually indicative of incurable disease. 
EUS-FNA of low-volume ascites can be performed 
safely.
26
 
Visualisation of gastric lesions during EUS is 
facilitated by aspiration of air and instillation of de-
aerated water into the stomach to submerge the lesions 
completely, thus allowing better acoustic coupling. With 
the standard echoendoscope, five distinct layers are seen, 
with 3 hyperechoic alternating with 2 hypoechoic layers. 
The first 2 layers represent the mucosa, the third layer 
represents the submucosa, the fourth layer is the 
muscularis propria and the last layer is the serosa. Table 
1 describes the T staging of gastric cancer. Tumors 
confined to the mucosa can be treated with EMR while 
those involving the submucosa carry a 20% risk of LN 
involvement and therefore require surgery.
27
 
Perigastric and regional (celiac axis, gastrohepatic 
ligament) LN are next assessed (Figure 2). Suspicious 
LN features during endosonography include 
hypoechogenicity, sharp borders, round shape and size 
>10mm. All 4 features are present in only 25% of 
malignant LN, and FNA of nodes with any of these 
features is necessary to confirm or exclude malignancy.
28
 
Distant metastasis (M) staging by checking the left lobe 
of the liver, the peritoneum, the pleural layers of the lung, 
and mediastinal LN is the final step. The finding of 
malignant ascites, pleural effusion and malignant 
mediastinal nodes is an indication for neoadjuvant or 
adjuvant treatment.
29
 
 
Rectal cancer 
Rectal cancer represents 5% of malignant tumors 
and is the fifth commonest cancer in adults.
30
 Staging of 
rectal cancer identifies patients with locally invasive 
tumors who should be treated with neoadjuvant therapy 
before surgery (Figure 3).
  
 
Figure 3: Management of Rectal Cancer – from staging 
to treatment (CT Scan: Computed tomography scan; 
EUS +/- FNA: Endoscopic ultrasound with or without 
Fine Needle Aspiration; EMR: Endoscopic Mucosal 
Resection; T1-Tumor invades lamina propria or 
submucosa; T2: Tmor invades muscularis propria; T3-
Tumor penetrates serosa; T4-Tumor invades adjacent 
structures; N0 – No regional lymph node metastases; N1 
– Metastases in 1-3 regional nodes; N2 – Metastases in 
4 or more regional nodes; M0 – No distant metastases; 
Neoadjuvant therapy – chemotherapy and 
radiotherapy)
29 
 
 
The accuracy of EUS for T staging in rectal cancer 
is 85% while the accuracy for N staging is 75%. With 
the addition of FNA of LN, accuracy increases to 87%.
31
 
During EUS staging of rectal cancers, the relationship of 
the tumor with adjacent organs such as the prostate, 
bladder, and seminal vesicles in men and the bladder, 
vagina, cervix and uterus in women is assessed. The 
perirectal area is studied for the presence of suspicious 
LN or involvement of the iliac vessels. 
 
Rectal cancer is seen as a hypoechoic lesion that 
disrupts the rectal wall pattern. A tumor limited to the 
submucosa is classified as T1, while if it invades the 
muscularis propria, it is classified as T2. T3 tumors 
penetrate into surrounding fat while T4 lesions invade 
into adjacent organs. Both radial and linear EUS scopes 
can be used for staging rectal lesions; however FNA of 
lymph nodes can only be done with the linear scope. 
High-frequency mini-probes using the water-filling 
technique may be a better option for small lesions (<1-2 
cms). Alternatively, changing the patient position may 
allow better visualization of the lesion.
 
EUS is superior to CT and MRI for T staging of 
rectal tumors. In a meta-analysis (5000 patients), CT 
accurately T staged the tumor in 73% of cases and had 
accurate N staging in 22-73%.
32
 MRI also has poor 
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accuracy in T staging of rectal cancer (52-54%).
33
 A 
meta-analysis (42 studies) evaluating EUS in rectal 
tumors revealed sensitivities and specificities of 88% 
and 98% for T1, 81% and 96% for T2, 91% and 96% for 
T3 and 95% and 98% for T4 tumors.
34
 This increased 
accuracy translates into improved patient management 
with more patients undergoing neoadjuvant treatment 
with chemotherapy and radiotherapy before surgery and 
a more cost-effective strategy when combining initial 
abdominal CT (to exclude distant metastases) and EUS 
(for local staging).
35 
N staging with EUS has not been shown to be 
superior to other imaging modalities. The pooled 
sensitivity and specificity of EUS in diagnosing nodal 
involvement in rectal cancers were 73% (95% 
confidence interval [CI] 70.6-75.6) and 76% (95% CI 
73.5-78.0) with a pooled diagnostic odds ratio of 7.87 
(meta-analysis of 35 studies), which is similar to the 
accuracy of CT and MRI.
36
 However, FNA of suspicious 
lymph nodes improves accuracy to 87%.
37
 Benign 
perirectal nodes are not usually visualized by EUS. 
Therefore, finding perirectal nodes during EUS is 
sufficient to warrant sampling by FNA. 
Conclusion  
With its high sensitivity and specificity in tumor (T) 
staging, endosonography has become an essential tool in 
the staging of gastrointestinal luminal malignancies. 
EUS is also important in lymph node (N) staging as it 
allows FNA cytological sampling of suspicious nodes. 
However, distant metastases (M staging) should be 
excluded by abdominal and thoracic computed 
tomography (with or without PET) before EUS is carried 
out. 
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